Clinical trials: Metastatic Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors
The PRINCESS study is a hypothesis-generating, interventional, open-label, non pharmacological trial designed to characterize the translational and clinical implications of the regular assumptions of inulin on Gut Microbiota…
- Trial name
- PRINCESS (NCT05821751)
- Testing
- inulin, Pembrolizumab, Nivolumab
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Esophageal Cancer
Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00006245
- Testing
- alvocidib, paclitaxel
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03886181
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Head and Neck Cancer, Oral Complications
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00017511
- Testing
- cevimeline hydrochloride
- Where
- 71 sites in United States
- Sponsor
- Daiichi Sankyo
Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell…
- Conditions
- Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- NCT05077709
- Testing
- IO102-IO103 in combination with pembrolizumab
- Where
- 21 sites in United States, Spain and 1 more
- Volunteers
- 63 people
- Sponsor
- IO Biotech
Melanoma, Carcinoma, Non-Small- Cell Lung
A Study of SEA-CD40 Given With Other Drugs in Cancers
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial.
- Trial name
- NCT04993677
- Testing
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 77 people
- Sponsor
- Seagen Inc.
Non-small Cell Lung Cancer
Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer
Based on the existing research results, Osimertinibi is effective not only for patients with sensitizing EGFR mutations, but also for other less common EGFR mutations.
- Trial name
- NCT03460275
- Testing
- Osimertinib Mesylate Tablets
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Various Advanced Cancer
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus…
- Trial name
- CheckMate 648 (NCT03143153)
- Testing
- Nivolumab, Ipilimumab, Cisplatin
- Where
- 190 sites in United States, Argentina and 25 more
- Volunteers
- 970 people
- Sponsor
- Bristol-Myers Squibb
Brain Tumors, Central Nervous System Tumors
Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma
RATIONALE: Electroacupuncture may help to reduce or prevent delayed nausea and vomiting in patients treated with chemotherapy. PURPOSE: This randomized clinical trial is studying the effectiveness of electroacupuncture in…
- Conditions
- Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00040911
- Testing
- electroacupuncture therapy, quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Children's Oncology Group
Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy.
- Trial name
- NCT05283226
- Testing
- NRC-2694-A, Paclitaxel
- Where
- 13 sites in United States, India
- Volunteers
- 21 people
- Sponsor
- NATCO Pharma Ltd.
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Carcinoma of Unknown Primary
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
RATIONALE: Drugs used in chemotherapy such as gemcitabine and irinotecan use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00066781
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms
The Diagnostic Value of PET/MRI in Head and Neck Cancer
This study investigates the diagnostic value of PET/MRI for cervical lymph node metastases from head and neck squamous cell carcinomas.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymph Node Metastases
- Trial name
- NCT04117139
- Testing
- PET/MRI
- Where
- Denmark
- Volunteers
- 142 people
- Sponsor
- Odense University Hospital
Esophageal Cancer, Gastric Cancer
S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00012363
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- 96 sites in United States
- Volunteers
- 61 people
- Sponsor
- SWOG Cancer Research Network
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102/SHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell…
- Trial name
- NCT07059221
- Testing
- SHR-A2102, Adebrelimab, Cetuximab
- Where
- 2 sites in China
- Volunteers
- 210 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
Durvalumab and Tremelimumab in combination with first-line chemotherapy in the following indications: Ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC and gastric/GEJ cancer, PDAC, ESCC.
- Conditions
- Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms
- Trial name
- NCT02658214
- Testing
- paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin
- Where
- 6 sites in Japan, South Korea
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC
This study is the first clinical study in PD-1 resistant patients with head and neck squamous cell carcinoma with drugs targeting EGFR signaling pathway combined with CDK4/6 inhibitors, which explores the new combination…
- Trial name
- NCT05721443
- Testing
- Dalpiciclib+cetuximab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Skin Cancer, Cutaneous Tumor
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors
- Conditions
- Skin Cancer, Cutaneous Tumor, Cutaneous Metastasis
- Trial name
- NCT04068155
- Testing
- DaRT- Diffusing Alpha-emitters Radiation Therapy
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Alpha Tau Medical LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.